Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer

Introduction: The RATIONALE-309 trial confirmed the significant efficacy and safety of tislelizumab plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). However, the economic benefits of this regimen are unclear. Therefore, this study aimed to evaluate the c...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Zhengda Pei, Ningping Xiao, Pei Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Subjects:	recurrent or metastatic nasopharyngeal carcinoma tislelizumab cost-effectiveness quality-adjusted life-years incremental cost-effectiveness ratio
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1265784/full